InflaRx Receives WHO Granted Generic Name 'izicopan'
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
InflaRx announced that the World Health Organization has granted the international nonproprietary, or generic, name of "izicopan" to the company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO's Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances. In the next step of this process, the name "izicopan" will be published in the recommended list of INNs.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on IFRX
Wall Street analysts forecast IFRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IFRX is 12.67 USD with a low forecast of 6.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.911
Low
6.00
Averages
12.67
High
24.00
Current: 0.911
Low
6.00
Averages
12.67
High
24.00
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InflaRx to Participate in Investor Conferences
- Investor Conference Schedule: InflaRx will participate in the Guggenheim Securities Biotech Summit on February 11-12, 2026, in New York, conducting one-on-one investor meetings on February 11 to enhance engagement and transparency with investors.
- Virtual Conference Participation: The company will also attend the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with a virtual presentation on February 25, further expanding its investor base.
- Product Development Progress: InflaRx's lead program, izicopan (INF904), an orally administered small molecule inhibitor, has shown promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies, expected to provide treatment options for various inflammatory diseases.
- Innovative Drug Development: The company has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated disease-modifying activity and tolerability in multiple clinical studies, highlighting its innovative potential in anti-inflammatory therapies.
Continue Reading
InflaRx Cuts 30% Workforce to Focus on Izicopan Development
- Cost-Cutting Measures: InflaRx announced a 30% workforce reduction and significant cuts to Gohibic-related commercial spending to enhance capital efficiency and support further development of izicopan, expecting a one-time charge of approximately $7 million.
- Cash Flow Outlook: Following the restructuring, InflaRx anticipates its cash runway will extend into mid-2027, and despite reduced spending, it will continue to support the BARDA-sponsored Gohibic clinical trial, ensuring its availability under emergency use authorization in the U.S.
- R&D Priority Shift: The company is prioritizing izicopan, planning to advance its development in hidradenitis suppurativa and other inflammatory and immunology indications, demonstrating a strong commitment to new drug development.
- Market Opportunity Assessment: InflaRx continues to evaluate partnership opportunities for Gohibic in both the U.S. and Europe and plans to engage with the FDA on a potential development path for vilobelimab in pyoderma gangrenosum, showcasing its adaptability in the market.
Continue Reading